Studies have suggested a strong "placebo effect" in the treatment of interstitial cystitis/bladder pain syndrome.
Johns Hopkins University in Baltimore on October 15 will launch the world's first institute devoted to bladder cancer.
Investigators report earlier bladder tumor relapse and higher risk of T-stage progression.
Keytruda (pembrolizumab) shows promising results for the treatment of PD-L1 positive bladder cancer.
In adjusted analyses, female transplant recipients had a significantly increased risk of urologic cancer and men did not.
It is associated with a 20-fold increased likelihood of the malignancy, British study shows.
Studies show integrated program effective for depression in patients with cancer.
As body mass index increases, so does the risk of kidney and bladder cancers in men and stomach, ovarian, and colon cancers in women.
Study reveals a 2-fold greater likelihood of primary kidney and bladder cancer compared with men in the general population.
Current smoking and smoking cessation prior to diagnosis does not alter risk of recurrence or progression of non-muscle-invasive bladder cancer.
Study shows a significantly better 5-year cancer-specific survival rate compared with radical cystectomy.
Use of the drug reduced the risk of recurrence and cancer-related mortality in diabetic patients undergoing radical cystectomy.
Meta-analysis demonstrates a protective effect with high intake.
Their risk of death is 40% lower than that of patients who are not obese, study shows.
Venous thromboembolism is more likely to occur in patients with neurologic comorbidities and increased operative time.
It offers a survival benefit regardless of age, but is used less often in patients aged 70 years and older than in younger patients.